Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

R&D

PhRMA Announces 2017 Research & Hope Award Honorees; Releases ‘Medicines in Development for Mental Illnesses Report’

Washington, DC, October 11, 2017 — As part of Mental Health Awareness Week, Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday announced it is recognizing and honoring five individuals who are working tirelessly to advocate for patients, fight stigma surrounding mental illnesses and advance research at our 2017 Research & Hope Awards.

In addition, PhRMA said that America’s biopharmaceutical companies are committed to alleviating the considerable burden of mental illness and bringing cutting-edge medicines and new treatments to patients.

According to a new report — “Medicines in Development for Mental Illnesses 2017 Report” — released on October 10, there are more than 140 medicines in development to treat mental illnesses such as anxiety, depression, schizophrenia and more. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, September 16, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

New Report: More Than 50 Medicines and Vaccines in Development for HIV Infection, Treatment and Prevention

Washington, DC, June 30, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that America’s biopharmaceutical companies are continuing the fight to conquer the human immunodeficiency virus (HIV), which can develop into acquired immune deficiency syndrome (AIDS).

According to a new report released on June 27 by PhRMA in partnership with The AIDS Institute, 52 medicines and vaccines are currently in development to help treat and prevent the infection.

Among the 52 medicines in development for HIV, there are 32 antiretrovirals and antivirals, 16 vaccines and four cell therapies, including a potential first-in-class medicine intended to prevent HIV from attaching to new cells and breaking through the cell membrane. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, June 28, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) today released a new report titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 New Jersey patients participate in clinical trials around the state, generating $617 million in economic growth.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas: Continue reading

Celebrating Failure in a Tough Drug Industry; As Few as 1 Out of 10,000 Compounds Tested Get FDA Approval

New York, NY, March 9, 2017 — Jonathan D. Rockoff reports in The Wall Street Journal after making the difficult decision to scrap a once-promising drug program, the biotech firm Ironwood Pharmaceuticals in Cambridge, Mass., did something unusual: It gathered to celebrate.

With dozens of staffers in attendance, the “drug wake” at Ironwood featured seven-layer dip, homemade cupcakes and a bittersweet send-off.

“It’s hard to say goodbye, so I won’t,” said Mark Charest, who works on regulatory affairs at the company.  “I’ll say, ‘Thank you—thank you to the peptide.’” Continue reading

R&D Council of New Jersey Accepting 2017 Edison Patent Award Submission Until May 26

Chatham, NJ, February 17, 2017 ― The Research & Development Council of New Jersey is now accepting, until May 26, submissions for its 2017 Edison Patent Awards.

To learn more or to apply for the 2017 Edison Patent Awards, click here.

Winners will be honored at the annual Edison Patent Awards Ceremony & Reception on November 2. Continue reading

Princeton University and Benefunder Agreement Offers Opportunities to Support Research

Princeton, NJ, February 14, 2017 — Princeton University has entered into an agreement with Benefunder to offer the opportunity for donors to support Princeton’s faculty engaged in leading-edge research and innovation programs through Benefunder’s philanthropic “marketplace.”

Benefunder provides a targeted approach for donors who want to focus their support on research and innovation that addresses causes about which they feel most passionate. Continue reading

Princeton, Rowan and Rutgers-Camden Ranked High for Academic R&D Expenditures in the Life Sciences for Region

Glassboro, NJ, February 13, 2017 — The Greater Philadelphia Region Life Sciences Report ranks Rowan University seventh among 19 colleges and universities in the region in R&D expenditures related to life sciences, third among the public institutions.

Princeton University and Rutgers-Camden also were included on the list, which is published on page 30 of the report.

The ranking is based on 2014 figures from the National Science Foundation and includes funds spent on biological sciences, chemical engineering, chemistry, medical sciences and other life sciences. Continue reading

Bloomberg Index: New Jersey 4th Most Innovative State; Massachusetts Is No. 1 Followed by California

New Jersey pin horizontalNew York, NY, January 24, 2017 — According to the latest Bloomberg Index published in December 2016, New Jersey is the fourth most innovative state in the country.

Massachusetts, fueled by its higher-education institutions and an unemployment rate that is almost two points below the national average, was once again recognized as the top state for innovation with a total score of 94.82.

California and Washington followed Massachusetts in the rankings. Continue reading

PhRMA: Three Things to Know About 2016 Drug Approvals

phrma-logo-whiteWashington, DC, January 10, 2017 — PhRMA Director of Public Affairs Andrew Powaleny writes In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need.

These much-needed new treatments include medicines for multiple sclerosis, chronic lymphocytic leukemia, ovarian and bladder cancer and the very rare spinal muscular atrophy (SMA).

Among these new medicines, more than a third are treatments for rare diseases and more than one-third are first-in-class, meaning they use a new, unique approach to treating an illness that has never before been available. Continue reading